¼¶±ð: СÓÞÓÞ
UID: 69782
¾«»ª: 0
·¢Ìû: 210
ÍþÍû: -4892 µã
»ý·Öת»»
ÓÞÓÞ±Ò: -4850 YYB
ÔÚÏß³äÖµ
¹±Ï×Öµ: 0 µã
ÔÚÏßʱ¼ä: 139(Сʱ)
×¢²áʱ¼ä: 2009-05-27
×îºóµÇ¼: 2010-03-14
Â¥Ö÷  ·¢±íÓÚ: 2009-07-11 14:40

 ÉúÎïҽѧӢÓï´Ê»ã·­ÒëÄѵã2-----ҽѧÉúÃü¿Æѧרҵ±Ø¶Á£¨¸öÈËÊղأ©

ÐÎÈÝ´Ê
ÉúÎïҽѧÂÛÖøÖеÄÐÎÈÝ´ÊÖ÷ÒªÓÃÓÚ˵Ã÷ÊÂÎïµÄÌØÕ÷¡¢ÌØÐÔ,ÓÐЩÐÎÈÝ´ÊÄܺܺõØÆðµ½Ëõ¶Ì¾ä³¤,ÓªÔìÓï¾³µÄ×÷Óá£Ò»Ð©ÐÎÈÝ´ÊÔÚÉúÎïҽѧÂÛÖøÖеÄÒâ˼ÓëÔÚÒ»°ãÎÄÏ×ÖеÄÒâ˼»áÓкܴó²»Í¬,Èç·­Òë²»µ±,»áÁîÒëÎÄÉúÓ²»Þɬ,º¬»ì²»Çå,Òò´ËÖ»ÓаÑÎÕÆäÄÚÔÚº­Òå,ͨ¹ýÁªÏµ¾ßÌåҽѧ֪ʶ,½«ÆäÒë×÷·ûºÏÉúÎïҽѧ±ê×¼µÄººÓï²ÅÄÜ´ïµ½·­ÒëЧ¹û¡£Àý1 Parallel ult rast ructural studies ereperformed upon cerebral arteries and their adja2cent perivascular subarachnoid spaces.ÒëÎÄ: (ÎÒÃÇ) ͬʱ¶ÔÄÔ¶¯Âö¼°ÆäÁÚ½üµÄѪ¹ÜÖÜΧÖëÍøĤÏÂÇ»½øÐÐÁ˳¬Î¢½á¹¹Ñо¿¡£·ÖÎö:parallel Ô­ÒåÊÇ¡°Æ½ÐеÄ,ÏàͬµÄ¡±,±¾¾äͨ¹ýparallel ´«´ïÁËÁ½¸öÒâ˼: 1. ³¬Î¢½á¹¹µÄÑо¿Éæ¼°ÄÔ¶¯ÂöºÍÆäÁÙ½üµÄѪ¹ÜÖÜΧÖëÍøĤÏÂÇ»;2. ¶ÔÕâÁ½¸ö²¿Î»µÄÑо¿¾ßÓÐͬµÈÖØÒªµÄÒâÒå,Òò´Ë·­ÒëʱҪ****************¹ËÕâÁ½²ãº­Òå¡£Àý2 Convincing evidence indicates that lipidperoxide and f ree radical accumulation in thewalls of cerebral arteries exposed to a degradingsubarachnoid blood clot are i ntegral component sin the development of cerebral vasospa.ÒëÎÄ:ÓÐÈ·ÔäÖ¤¾ÝÏÔʾ½Ó´¥Á˽µ½âÖеÄÖëÍøĤÏÂǻѪÄý¿éµÄÄÔ¶¯Âö¹Ü±ÚÖеÄÖ¬ÖʹýÑõ»¯ÎïºÍ×ÔÓÉ»ù¾Û¼¯ÊÇÄÔѪ¹Ü¾·ÂνøÕ¹ÖÐÁ½¸öЭͬ×÷Óá¢Ãܲ»¿É·ÖµÄ×é³É²¿·Ö¡£·ÖÎö: integral Ô­ÒåÊÇ¡°ÍêÕû¡±¡£±¾¾äͨ¹ýintegral ´«´ïÁËÁ½¸öÒâ˼: 1. Ö¬ÖʹýÑõ»¯ÎïºÍ×ÔÓÉ»ùµÄ¾Û¼¯ÔÚÄÔѪ¹Ü¾·Âη¢ÉúÖÐÊÇÃܲ»¿É·ÖµÄ;2. Á½Õß´æÔÚЭͬ×÷ÓÃÇé¿ö,Òò´Ë·­Òë³É¡°ÍêÕû¡±¹ýÓÚ³éÏó,²»ÄÜ׼ȷµØ±í´ïÕâ¾ä»°µÄÒâ˼,¹Ê½«ÉÏÊöÁ½²ãÒâ˼,Òë×÷¡°Ð­Í¬×÷ÓÃ, Ãܲ»¿É·Ö¡±¡£Àý3 Several studies have reported that neu2ronal calcium overload is a reliable feature of ex2perimental TBI (t raumatic brain injury) .ÒëÎÄ:һЩÑо¿±¨µ¼Éñ¾­Ôª¸ÆÀë×Ó³¬ÔØÊÇ´´ÉËÐÔÄÔËðÉ˵ÄÃ÷È·ÌØÕ÷¡£·ÖÎö:reliable ͨ³£Ö¸¡°¿É¿¿µÄ,¿ÉÐÅÀµµÄ¡±,±¾¾äÓá°reliable¡±ÐÞÊÎfeature ,Ò»·½Ãæ˵Ã÷ÕâЩÑо¿±¨¸æµÄ¿É¿¿ÐÔ,ͬʱǿµ÷ÕâÒ»ÌØÕ÷ÊÇÈ·¶¨ÎÞÒɵġ£Èç¹ûÖ±ÒëΪ¡°¿É¿¿µÄÌØÕ÷¡±,Ôò²»·ûºÏººÓï±í´ïÏ°¹ß,Òò´ËÒë×÷¡°Ã÷È·¡±¾Í·´Ó³ÁËÑо¿ÐÅÏ¢µÄ¿É¿¿ÐÔºÍÌØÕ÷µÄÏÊÃ÷ÐÔ¡£Àý4 Thus , different magnitudes of injurymay t rigger divergent signaling pathways thatultimately lead to calpain and/ or caspase-3 medi2ated cell death.ÒëÎÄ:Òò´Ë,²»Í¬³Ì¶ÈµÄËðÉË¿ÉÄÜ´¥·¢¸÷×Ô²»Í¬µÄÐźŴ«µ¼Í¨Â·²¢×îÖÕµ¼ÖÂcalpain ºÍ/ »òcaspase-3 ½éµ¼µÄϸ°ûËÀÍö¡£·ÖÎö:divergent ͨ³£Ö¸¡°·ÖÆçµÄ,·Ö²æµÄ¡±,ËüÐÎÏóµØ±íÏÖÁËÐźŴ«µ¼´Óijһ·´Ó¦µã¿ªÊ¼Ïò¸÷×Ô²»Í¬·½Ïò·¢Õ¹µÄ¶¯Ì¬¹ý³Ì,µ«ÈçºÎ°ÑÕâ¡°Éñ»á¡±Á˵ÄÒâ˼¾ßÌå³ÉººÓï,ÕâÀïÒýÉêÒë×÷¡°¸÷×Ô²»Í¬¡±,ʹÒâ˼¸ü¼Ó¾ßÌ廯¡£
¸±´Ê
һЩ¸±´ÊµÄÇÉÃîÓ¦Óò»½öÌåÏÖ×÷Õßд×÷¼¼ÄÜ,¶øÇÒÍùÍù¿ÉʹÎÄÕÂÔöÉ«,ÔÚÓ¢ÓïÉúÎïҽѧÂÛÖøÖг£Æðµ½´«´ïÏÒÍâÖ®ÒôµÄЧ¹û,Ò²ÊǶԶÁÕßÀí½âÁ¦µÄ¼ìÑé¡£ÂÛÖøÖиö±ð¸±´ÊµÄººÒëÐèÒªÒëÕß½áºÏҽѧ֪ʶ,ͨ¹ý×ÔÉíµÄÁìÎò½øÐкÏÀíµÄ·­Òë,ÒÔʹÒëÎÄÂöÂçÇåÎú,ͨË×Ò׶®¡£Àý1 Subarachnoid hemorrhage was remote2ly induced via perforation of the circle of Willis ofrat s with an endovascular suture during Mimaging.ÒëÎÄ:MR(ºË´Å¹²Õñ) ³ÉÏñÆÚ¼ä,ͨ¹ýѪ¹ÜÄÚÖÃÈë·ìÏßÔÚÔ¶¶Ë´ÌÆÆ´óÊóWillis »·(´óÄÔ¶¯Âö»·) ,ÒýÆðÖëÍøĤÏÂÇ»³öѪ¡£·ÖÎö: remotely ÊÇ¡°Ò£Ô¶µØ,ƫƧµØ¡±Òâ˼,Èç¹ûÉúÓ²µØ·­Òë,·ÇרҵÈËÔ±ºÜÄÑÀí½âÒ£Ô¶ºÍÓÕµ¼Ö®¼äÊÇÔõÑùµÄÒ»ÖÖģʽ¡£½âÆÊѧÉÏWillis»·Î»ÓÚ­ÄÚ,·ìÏßÖ»ÄÜͨ¹ý­ÍâѪ¹ÜÏò­ÄÚÑÓÉì½øÈëWillis »·,´Ëʱ·ìÏßµÄÍ·¶ËÏà¶ÔÓÚÆä²å
Èëµãȷʵ´¦ÓÚ¡°Ò£Ô¶¡±µÄ״̬,Òò´Ë·­Òë³É¡°ÔÚÔ¶¶Ë¡±·ûºÏ½âÆÊѧÌصã,Ò²Ò×Àí½â¡£Àý2 a. The dosages of nimodipine usedwere 3 to 7 times greater than that reported tobe therapeutially effective in reducing the inci2dence of severe deficit s f rom vasospa in pa2tient s with aneuryal subarachnoid hemor2rhageb. When the COOH- terminal portion of
Rho- kinase is deleted , the NH2- terminal portioncontaining the catalytic domain of Rho- kinasebecomes constit utively active.ÒëÎÄ:a. ºÍ±¨µÀµÄ¶Ô½µµÍ¶¯ÂöÁöÐÔÖëÍøĤÏÂÇ»³öѪ²¡ÈËѪ¹Ü¾·ÂÎÒýÆðµÄÑÏÖع¦Äܲ»×ã²úÉúÁÆЧµÄ¼ÁÁ¿Ïà±È,±¾Ñо¿Ê¹ÓõÄÄáĪµØƽ¼ÁÁ¿Òª¸ß³ö3-7 ±¶¡£b. Rho ¼¤Ã¸Öк¬ÓеÄCOOH-Ä©¶Ë²¿·Ö±»È¥³ýºó,º¬Óд߻¯ÑÇ»ùµÄ¼¤Ã¸NH2 Ä©¶Ë²¿·Ö¾Í³ÉÁËøµÄ»îÐԽṹ¡£·ÖÎö:ÓÐЩ¸±´Êͨ¹ýÐÞÊÎÐÎÈÝ´Ê¿ÉÒÔÓªÔìÒ»ÖÖÓï¾³,ÕâÔÚÓ¢ÓïÂÛÖøÖÐÂżû²»ÏÊ¡£µ«ººÒëÈç°´¸±´Ê·­ÒëÍùÍù¹ýÓÚÀÛ׸,¹Ê¿É¸ù¾Ý¾ßÌåÇé¿ö½«¸±´Êת»¯ÎªººÓïµÄÐÎÈÝ´Ê,ÆäÐÞÊεÄÐÎÈÝ´Ê¿ÉÒë³ÉÏàÓ¦µÄÃû´Ê(a) ,»ò½«¸±´Ê»¹Ô­ÎªÃû´Ê,ÓÃÆäÐÞÊεÄÔ­ÐÎÈÝ´ÊÐÞÊθ*************************û´Ê(b) ¡£
¼¶±ð: СÓÞÓÞ
״̬: δǩµ½ - [33Ìì/33´Î]
UID: 69782
¾«»ª: 0
·¢Ìû: 210
ÍþÍû: -4892 µã
»ý·Öת»»
ÓÞÓÞ±Ò: -4850 YYB
ÔÚÏß³äÖµ
¹±Ï×Öµ: 0 µã
ÔÚÏßʱ¼ä: 139(Сʱ)
×¢²áʱ¼ä: 2009-05-27
×îºóµÇ¼: 2010-03-14
1Â¥  ·¢±íÓÚ: 2009-07-12 00:59
¿ª¾íÓÐÒ棡£¡¿´¿´°É
·ÖÏí:

ÓÞÓÞѧ԰ÊôÓÚ´¿Ñ§Êõ¡¢·Ç¾­ÓªÐÔרҵÍøÕ¾£¬ÎÞÈκÎÉÌÒµÐÔÖÊ£¬´ó¼Ò³öÓÚѧϰºÍ¿ÆÑÐÄ¿µÄ½øÐн»Á÷ÌÖÂÛ¡£

ÈçÓÐÉæÇÖ·¸Öø×÷ȨÈ˵İæȨµÈÐÅÏ¢£¬Ç뼰ʱÀ´ÐŸæÖª£¬ÎÒÃǽ«Á¢¿Ì´ÓÍøÕ¾ÉÏɾ³ý£¬²¢ÏòËùÓгְæȨÕßÖÂ×îÉîǸÒ⣬лл¡£